· Published by Health Canada · Official notice
This is duplicated text of a letter from Janssen Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
July 28, 2014
Subject: DURAGESIC® MAT (fentanyl transdermal system) - New ink colour (dark green) on all patch strengths
Janssen Inc., in consultation with Health Canada, would like to inform you about possible dosing errors with changes to ink printing on the patches of DURAGESIC® MAT.
Currently, different colours of ink in combination with the text on the patch are used to identify the different strengths of DURAGESIC® MAT (12, 25, 50, 75 and 100 mcg/h). If you are a current user of DURAGESIC® MAT, you should be aware that one shade of dark green ink, intended to make it easier to see the patch, will now be used on all strengths. The product carton and pouch will still use the different colours of ink to help in differentiating patch strengths.
To ensure your safety, please note the following important information:
Graphics of the new dark green ink for various patch strengths are provided below for your reference.
Patches with the new dark green colour ink will enter the market in late July.
Health Canada is working with Janssen Inc., the Market Authorization Holder for DURAGESIC® MAT, on revisions to the outer packaging to highlight the change to darker green ink printing on all strengths of the patch.
DURAGESIC® MAT is used for the management of persistent, moderate to severe chronic pain that cannot be managed by other means such as opioid combination products or immediate-release opioids.
Accidental exposure can occur by unintentional patch transfer to a non-patch wearer while hugging, sharing a bed or moving a patient. Accidental ingestion or use of patches can also occur from patches that have either fallen off or been inappropriately stored or discarded.
Additional information on the safe storage, handling, use and disposal of fentanyl patches to reduce the risk of accidental exposure is available on the Healthy Canadians Web site.
Janssen Inc. has provided this information to doctors and pharmacists across Canada. Product details are included in the DURAGESIC® MAT consumer information document, available at the Janssen Canada Web site. For more information, patients should consult their healthcare professional.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Any case of dosing errors or other serious or unexpected adverse reactions in patients receiving DURAGESIC® MAT should be reported to Janssen Inc. or Health Canada. Medication errors can also be reported to the Institute for Safe Medication Practices (ISMP) Canada through the Canadian Medication Incident Reporting and Prevention System.
Drug Safety Department
Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
Or call toll free at 1-866-825-7122
Or email to dsscan@joica.jnj.com
Or fax to 1-866-767-5865
You can report any suspected side effect associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Should you have any questions or require additional information regarding the use of DURAGESIC® MAT, please contact Janssen Inc. Medical Information Department at 1-800-567-3331 or 1-800-387-8781 from 8:30 a.m. to 4:30 p.m. Monday to Friday Eastern Standard Time (EST). A copy of this letter is also available on the Janssen Web site and on the Health Canada Web site.
original signed by
Cathy Lau, Ph.D.
Vice President
Regulatory Affairs and Quality Management
All trademarks used under license.
| Strength | Current Colour | New Colour |
|---|---|---|
| Duragesic 12 mcg/h (fentanyl transdermal) | light orange | dark green |
| Duragesic 25 mcg/h (fentanyl transdermal) | light pink | |
| Duragesic 50 mcg/h (fentanyl transdermal) | light green | |
| Duragesic 75 mcg/h (fentanyl transdermal) | light blue | |
| Duragesic 100 mcg/h (fentanyl transdermal) | light grey |